BlackRock’s Moderna MRNA Stock Holding History

BlackRock’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-7,000	Closed	-$2.69M	–	5834
2021 Q3	$2.69M	Buy	+7,000	New	+$2.58M	﹤0.01%	4189

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

BlackRock's MRNA Position: Q1 2026 in Review

BlackRock reduced its Moderna (MRNA) stake by 8.8% in Q1 2026, selling an estimated $134M and leaving 29,635,876 shares worth $1.51B. The position accounts for 0.03% of the portfolio, ranked #504.

BlackRock first reported a position in MRNA in Q4 2018 and has held it in 30 quarters since. The position peaked at $10.3B in Q3 2021. 723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

BlackRock held 29,635,876 shares of Moderna worth $1.51B as of Q1 2026.
BlackRock sold 2,869,857 Moderna shares in Q1 2026, an estimated $134M.
Moderna made up 0.03% of BlackRock's portfolio in Q1 2026, its #504 holding.
BlackRock first reported a position in Moderna in Q4 2018 and has held it in 30 quarters since.
BlackRock's Moderna position peaked at $10.3B in Q3 2021.
723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.